enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
3.550
-0.130 (-3.53%)
May 6, 2025, 11:53 AM EDT - Market open
enGene Holdings Employees
As of October 31, 2024, enGene Holdings had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 24 or 72.73% compared to the previous year.
Employees
57
Change (1Y)
24
Growth (1Y)
72.73%
Revenue / Employee
n/a
Profits / Employee
-$1,211,351
Market Cap
180.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 57 | 24 | 72.73% |
| Oct 31, 2023 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ENGN News
- 8 days ago - enGene to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum - Business Wire
- 2 months ago - enGene Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - enGene to Participate in the Leerink Partners Global Healthcare Conference - Business Wire
- 2 months ago - enGene Holdings Inc.: Unknown Company Which Looks Like A Catch - Seeking Alpha
- 3 months ago - enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 3 months ago - enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Business Wire